Zealand Pharma Announces Results From Phase 3 Trial Of Glepaglutide; Glepaglutide Treatment Met Primary Endpoint

Zealand Pharma Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (EASE 1)

• Glepaglutide treatment met the primary endpoint with twice weekly dosing achieving a statistically significant reduction in weekly parenteral support volume by 5.13 Liters/week from baseline at 24 weeks
• 66% of patients in the twice weekly group had a clinically meaningful response (>20% reduction in parenteral support volume)
• In total 9 patients treated with glepaglutide were weaned off parenteral support, while no placebo treated patients were able to wean off parenteral support
• Glepaglutide treatment was assessed as safe and was well-tolerated in the trial
• Conference call scheduled today at 8:00 a.m. ET / 2:00 p.m. CET